February 15th, 2016
Venous haemodynamic and cerebrospinal fluid anomalies associated with multiple sclerosis
This critical synopsis of prior work by Clive Beggs is submitted in support of a PhD by published work. The work focuses on venous and cerebrospinal fluid (CSF) anomalies associated with multiple sclerosis (MS) and other neurological diseases. MS is characterized by focal inflammatory lesions, which are often venocentric. Recently a vascular syndrome, chronic cerebrospinal venous insufficiency (CCSVI) has been linked with MS. This syndrome, which is characterized by constricted cerebral venous outflow, has become mired in controversy, with various studies producing conflicting findings, with the result that the science associated with CCSVI has become obscured. Clive Beggs work seeks to bring clarity to the debate surrounding CCSVI by characterizing physiological changes associated with constricted cerebral venous outflow.
February 10, 2016
New Research: MS as a Disease of Endothelial Dysfunction
In a paper published in the Journal of Neurological Sciences, researchers looked at serum markers of healthy individuals and compared them to people with MS. What they found were that in people with MS, there are circulating microparticles in the blood that aren’t found in healthy people. These markers (CD31+/CD51+/CD61+/CD54+) are microparticles which are shed from the lining of the damaged endothelium. We see the same markers in cardiovascular disease. These markers are associated with coronary artery disease, hypercoagulation, thrombosis (clotting) and stroke:
February 5, 2016
Parkinson’s May Begin in Gut and Spread to the Brain Via the Vagus Nerve
A major epidemiological registry-based study from Aarhus University and Aarhus University Hospital indicates that Parkinson’s disease begins in the gastrointestinal tract; the study is the largest in the field so far.
The chronic neurodegenerative Parkinson’s disease affects an increasing number of people. However, scientists still do not know why some people develop Parkinson’s disease. Now researchers from Aarhus University and Aarhus University Hospital have taken an important step towards a better understanding of the disease:
January 19, 2016
Under Our Skin: The Untold Story of Lyme Disease
In this short clip from the award-winning 2008 documentary, Dr. Alan MacDonald discusses the links between Lyme Disease, Alzheimer’s, and Multiple Sclerosis.
June 1, 2015
Lymph vessels carrying immune cells are found in the brain. These vessels only function with healthy venous drainage. The fact that such vessels could have escaped detection when the lymphatic system has been so thoroughly mapped throughout the body is surprising on its own, but the true significance of the discovery lies in the effects it could have on the study and treatment of neurological diseases ranging from autism to Alzheimer’s disease to multiple sclerosis:
December 14, 2014
This week, the FDA formally approved the Hubbard Registry to treat and follow MS patients with abnormalities of their internal jugular and azygos veins. It has taken a year and a half of back and forth dialogue between the Hubbard Foundation and the FDA to reach this study approval.
Prior to May 2012, the Hubbard Registry was nationally collecting data from participating physicians, using an Internal Review Board (IRB) approval. Interventional radiologists and vascular diagnosticians were allowed to diagnose and treat venous abnormalities under the umbrella of this program. They compiled data on their procedures, which was collected by the Hubbard Foundation:
Research article indicating: The worse the venous obstruction, the less cerebral blood flow. Severity of CCSVI was directly related to severity of hypoperfusion in CBF
Several studies have reported hypoperfusion of the brain parenchyma in multiple sclerosis (MS) patients. We hypothesized a possible relationship between abnormal perfusion in MS and hampered venous outflow at the extracranial level, a condition possibly associated with MS and known as chronic cerebrospinal venous insufficiency (CCSVI):
March 27, 2014
The aim of the study was to investigate the Internal Jugular Veins dynamics using contrast enhanced ultrasonography in Multiple Sclerosis patients, clinically isolated syndrome patients and healthy controls. Contrast enhanced ultrasonography imaging of the Internal Jugular Vein was performed in fifty-eight patients with Multiple Sclerosis, seven clinically isolated syndrome patients and in thirteen healthy controls. Time-intensity curves were quantified using a semi-automated method and compared with clinical disease outcomes. Wash-out parameters were calculated and six Time-intensity curves shapes were created. Significantly reduction of wash-out rate in Internal Jugular Veins was detected in Multiple Sclerosis patients compared to healthy controls [22.2% (2.7%–65.9%) vs. 33.4% (16.2%–76.8%); P<0.005]. Internal Jugular Vein enhancement was heterogeneous in patients with Multiple Sclerosis and consisted of slow wash-out Time-intensity curves shapes, compared with almost only one type of Time-intensity curves shape in control subjects that correspond to fast enhancement and fast wash-out. The vein wash-in parameters were similar in Multiple Sclerosis group compared with controls. A significant correlation was found between Internal Jugular Vein wash-out and level of disability (R = −0.402, p<0.05). Contrast enhanced ultrasonography of the Internal Jugular Vein with time intensity curve analysis revealed alterations of cerebral venous outflow in Multiple Sclerosis patients, however mechanisms that determine this condition remains unclear:
World Congress of Phlebology meets in Boston; CCSVI found worldwide
More reproducible and objective CCSVI assessment is warranted also for planning treatments, in consequence of the inherent variability of the causes leading to restricted venous outflow from the brain:
August 7, 2013
Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI
New paper from PREMiSE study, published in BMC Neurology Journal–CCSVI exists, and it impairs blood outflow from the brain. “In addition, the findings from the 2 invasive techniques confirmed the existence of severe extracranial venous anomalies that significantly impaired normal blood outflow from the brain in this group of MS patients:
“We conclude that CCSVI can be definitively inserted among the medical entities.”
Taking into account the current epidemiological data, including studies on catheter venography, the autoptic findings, and the relationship between CCSVI and both hypoperfusion and cerebrospinal fluid flow, we conclude that CCSVI can be definitively inserted among the medical entities:
Angioplasty in MS patients with CCSVI increased CSF flow
Angioplasty in MS patients with CCSVI increased CSF flow and decreased CSF velocity, which are indicative of improved venous parenchyma drainage:
Treatment of the IJV and azygous veins in patients with CCSVI and MS
Endovascular treatment of the IJV and azygous veins in patients with CCSVI and MS is a safe procedure with no post-procedural complications followed by significant improvement of IJV flow haemodynamic parameters and decrease in the EDSS score:
Donate now to help make this fund a reality
There are many people waiting for this assistance. To contribute to the CCSVI Testing Fund, please donate on our website or send a check payable to Functional Health, Inc. P.O. Box 12278, Atlanta, GA 30355.
CCSVI Atlanta approved as a 501(c)(3) non-profit organization
Great news! CCSVI Atlanta has been approved as a 501(c)(3) non-profit organization. This enables individual contributions to be eligible as a tax deduction. We pledge that 100% of every dollar received in the CCSVI Testing Fund will go soley towards patients who need financial assistance for a CCSVI evaluation.
Endovascular treatment of CCSVI in patients with MS
Endovascular treatment of CCSVI in patients with MS appears to be a safe procedure resulting in significant clinical improvement:
Back from the 2012 ISNVD Conference
A lot of excitement about where CCSVI is evolving in regards to diagnosis, patient care and treatment.
The FDA approved the use of the special software & equipment that Dr. Zamboni’s team helped develop for evaluating blood flow in the DCVs. This part of the evaluation is one of the five criteria used to determine CCSVI. This software is a huge improvement over traditional means for evaluating the blood flow direction in the DCVs. At CCSVI Atlanta we include this evaluation of the DCVs in our exam.